{"id":"W4289522686","doi":"10.1182/blood.2021014586","title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma","keywords":"Medicine; Internal medicine; Hazard ratio; Gastroenterology; Azacitidine; Chemotherapy; Interim analysis; Neutropenia; Adverse effect; Surgery; Chemotherapy regimen; Randomized controlled trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008120744,0.00036424,0.001127321,0.00037588,0.0002480354,0.00002724122,0.0004054024,0.0001342272,0.0003919547],"category_scores_gemma":[0.001522026,0.0003543525,0.0005156519,0.0005596445,0.0001747189,0.0001025972,0.0001953799,0.0004254422,0.000005926116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002890528,"about_ca_system_score_gemma":0.0009263146,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008616703,"about_ca_topic_score_gemma":0.000006573217,"domain_scores_codex":[0.9969769,0.00009624271,0.0008385019,0.0006477336,0.0006562289,0.0007844012],"domain_scores_gemma":[0.996902,0.0008864547,0.0003040193,0.0006694173,0.0009513794,0.0002867511],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5037586,0.01185285,0.0001608153,0.001199772,0.001482138,0.0003457465,0.001812806,0.00003206305,0.3430348,0.0008327179,0.1228456,0.01264205],"study_design_scores_gemma":[0.6669283,0.02429917,0.00001920251,0.00008226876,0.0004401531,0.000166846,0.0009913273,0.0009159675,0.2122988,0.0003113915,0.09319701,0.0003495909],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803906,0.0003478826,0.002164675,0.00595915,0.0004285781,0.008133632,0.001897856,0.0001387806,0.0005388343],"genre_scores_gemma":[0.9759511,0.000310918,0.007238865,0.004504594,0.001957658,0.005936042,0.0016001,0.0002188535,0.002281809],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1631697,"threshold_uncertainty_score":0.9998909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03798504492468324,"score_gpt":0.3428577901550158,"score_spread":0.3048727452303326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}